Table 1.
Baseline characteristics of the patients.
Fig 1.
Box plots of elasticity values according to METAVIR hepatic fibrosis stage in patients with autoimmune liver disease (AILD) (A), autoimmune hepatitis (AIH) (B), and primary biliary cholangitis (PBC) (C). The Liver stiffness value was positively correlated with the stage of hepatic fibrosis.
Table 2.
Diagnostic performance of ElastPQ for hepatic fibrosis stage.
Table 3.
Regression analysis of the determinants for median ElastPQ value.
Fig 2.
Receiver operating characteristic (ROC) curves of elastography point quantification (ElastPQ) and serum fibrosis markers for assessing significant hepatic fibrosis (≥ F2) and cirrhosis (F4) in autoimmune liver disease (A, B), autoimmune hepatitis (C, D), and significant hepatic fibrosis (≥ F2) and advanced fibrosis (≥ F3) in primary biliary cholangitis (E, F). ElastPQ has shown better diagnostic performance for assessing hepatic fibrosis than serum fibrosis markers, aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4). APRI = (aspartate aminotransferase [AST] [IU/L] / upper normal limit of AST [IU/L]) / platelets [103/mm3] FIB-4 = (age [years] × AST [IU/L]) / (platelets [103/mm3] × alanine aminotransferase [ALT] [IU/L]1/2).
Table 4.
Comparison of AUC ElastPQ with APRI and FIB-4 to determine hepatic fibrosis.